Vol. 5 (04) pp. 1477-1484 DOI: 10.21474/IJAR01/3970

PLASMA OSTEOPONTIN AS A NOVEL DIAGNOSTIC BIOMARKER FOR EARLY DETECTION OF HEPATOCELLULAR CARCINOMA.

, and
  • Internal Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.
  • Public Health and Community Medicine Department, Faculty of Medicine, Benha University, Benha, Egypt.
25 Downloads 200 Views
Crossref

Download Full Paper (PDF)

Abstract

Background: Hepatocellular carcinoma (HCC) is a worldwide major health problem, with increasing prevalence and poor prognosis. As regard Egypt, HCC increased due to high prevalence of Hepatitis C virus (HCV) infection. Osteopontin (OPN) is a phosphorylated glycoprotein, which play an important role in the pathogenesis of different inflammatory and fibrotic processes. Recently, OPN has developed as a promising new biomarker for HCC. Aim: This study aimed to assess the value of OPN as a biomarker for early detection of HCC in HCV positive patients with cirrhosis. Method: This study included 60 persons, divided into 4 groups each of them included 15 persons; normal persons as a control, HCV positive patients without cirrhosis, HCV positive patients with cirrhosis, HCV positive patients with cirrhosis and complicated with HCC. For all groups, History, physical examination and radiological findings were collected. OPN and AFP levels were detected by ELISA. Results: HCC patients were more likely males with a mean age 61 years. . OPN level was significantly higher in the HCC group than other groups (P<0.001). In HCV positive patients OPN was more sensitive than AFP, but in cirrhotic patients AFP was more sensitive and specific, while both were equal in detection of patient with HCC. Conclusion: Plasma Osteopontin level seemed to be a biomarker for the detection of HCC in cirrhotic patients with HCV.

Keywords

Article Analytics

References

  1. El-Garem H, H Abdel-Hafez, A Foaud, W Al Akel and M Eldien Atia: Tissue biomarkers in the early detection of hepatocellular carcinoma among Egyptian patients with chronic hepatitis C: A possible genetic profile. Br. J. Med. Med. Res. 2013, 3(4): 1858-1870.
  2. Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB and Coebergh JW: EUROCARE Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995?99: results of the EUROCARE-4 study. Lancet Oncol. 2007; 8(9):773?83.
  3. Omar A, Abou-Alfa GK, Khairy A and Omar H: Risk factors for developing hepatocellular carcinoma in Egypt. Chin. Clin. Oncol. 2013; 2(4): 43.
  4. Bessa SS, Elwan NM and Suliman GA: Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch. Med. Res. 2010; 41(7):541?7.
  5. Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL: Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002; 36:1206?13.
  6. Liovet JM and Beaugrand M: Hepatocellular carcinoma: present status and future prospects. J. Hepatol. 2003; 38(Suppl 1): S136-S149.
  7. Szalay F: Hepatitis C virus infection and hepatocarcinogenesis. Orv. Hetil. 2010, 151(38): 1524-9.
  8. Bruix J and Sherman M: Management of hepatoclellular carcinoma: an update. Hepatology. 2011; 53(3):1020?2.
  9. Di Bisceglie AM: Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1): S104-7.
  10. Ryder SD: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut. 2003; 52 (suppl. III): 1-8.
  11. El-Serag HB and Davila JA: Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004; 39(3): 798-803.
  12. Senger DR, Wirth DF and Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 1979; 16(4): 885-93.
  13. Yang M, A Ramachandran, HM Yan, BL Woolbright and BL Copple: Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. Toxicol. Lett. 2014, 224(2): 186-195.
  14. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X: Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis infection. International journal of clinical practice. 2008; 62(7): 1056-62.
  15. Tajima K, R Ohashi, Y Sekido, T Hida and T Nara: Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene. 2010, 29(13): 1941-51.
  16. European Association for the Study of the Liver (EASL) and European Organization for Research and Treatment of Cancer (EORTC): EASL-EORTC Clinical Practice Guidelines: Management of hepatocelular carcinoma. J. Hepatol. 2012; 56(4):908?43.
  17. El-Zayadi AR, HM Badran, S Shawky, S Emara, A El-Bareedy and M Sobhi: Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol. Int. 2010, 4(2): 500-6.
  18. Akahoshi H, N Taura, T Ichikawa, H Miyaaki and M Akiyama: Differences in prognostic factors according to viral status in patients with hepatocellular carcinoma. Oncol. Rep. 2010, 23(5): 1317-23.
  19. Lopez JB: Recent development in the first detection of hepatocellular carcinoma. Clin. Biochem. Rev. 2005; 26(3): 65-79.
  20. Di Bisceglie AM: Epidemiology and clinical presentation of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 2002; 13(9 Pt 2):S169-71.
  21. Lehman EM, Soliman AS, Ismail K, Hablas A, Seifeldin IA, Ramadan M and El-Hamzawy H: Patterns of hepatocellular carcinoma incidence in Egypt from a population- based cancer registry. Hepatol. Res. 2008; 38(5):465- 73.
  22. Lopez JB: the value of liver function tests in hepatocellurlar carcinoma. Mabysian J. pathol. 1996; 18(2): 95-9.
  23. Sim?o A, Madaleno J, Silva N, Rodrigues F, Caseiro P, Costa JN and Carvalho A:? Plasma osteopontin is a biomarker for the severity of alcoholic liver cirrhosis, not for hepatocellular carcinoma screening. BMC Gastroenterology 2015; 15:73.
  24. Sun HY, Y Li, K Guo, XN Kang, C Sun and YK Liu: Identification of metastasis-related osteopontin expression and glycosylation in hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi 2011, 19(12): 904-7.
  25. Kim J, SS Ki, SD Lee, CJ Han and YC Kim: Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 2006, 101(9): 2051-9.
  26. Abu El Makarem MA, Abdel-Aleem A and Ali A: Diagnostic significance of plasma osteopontin in hepatitis C virus related hepatocellular carcinoma. Ann. Hepatol. 2011; 10(3): 296-305.
  27. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR and Sangrajrang S: Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012; 55(2): 483-90.
  28. Kawashima R, Mochida S, Matsui A, You LU, Tu ZY and Ishikawa K: Expression of osteopontin in Kupffer cells and hepatic macrophages and Stellate cells in rat liver after carbon tetrachloride intoxication: a possible factor for macrophage migration into hepatic necrotic areas. Biochem. Biophys. Res. Commun. 1999; 256(3):527?31.
  29. Mona Salema, Sahar Abdel Attia, Maisa El Razikyb, Samar Kamal Darweeshb and Marwa El Sharkawya: Clinical Significance of Plasma Osteopontin Level as a Biomarker of Hepatocellular Carcinoma Gastroenterology Research. 2013; 6(5):191-199.
  30. Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X and Sun HC: The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2006; 132(11):709-717.
  31. Zekri ARN, AA Bahnassy, HMA El-Din, HM Morsy, S Shaarawy, NZ Moharram and SS Daoud: Serum levels of β-catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncol. Rep. 2011, 26(4): 825-31.

How to Cite This Article

Mohamed El?Tantawy Ibrahim, Mohamed Ahmed Mohamed and Hanaa El-Sayed bayomy. (2017); PLASMA OSTEOPONTIN AS A NOVEL DIAGNOSTIC BIOMARKER FOR EARLY DETECTION OF HEPATOCELLULAR CARCINOMA., Int. J. of Adv. Res., 5 (04), 1477-1484, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/3970

Corresponding Author

Mohamed EL-Tantawy Ibrahim

Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.